{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10048","value":"31703"},{"groupId":"OG001","spread":"8294","value":"29057"}]}],"title":"Week 0 to Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"127581","value":"299071"},{"groupId":"OG001","spread":"93095","value":"289167"}]}],"title":"Week 0 to Week 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"316749","value":"582686"},{"groupId":"OG001","spread":"233411","value":"540375"}]}],"title":"Week 0 to Week 10"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with B-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG000","title":"B-cell Acute Lymphoblastic Leukemia (B-ALL)"},{"description":"Participants with T-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG001","title":"T-cell Acute Lymphoblastic Leukemia (T-ALL)"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetic (PK) population consisted of all participants from the AT population with at least 1 PK parameter available (isatuximab concentration). Only those participants with data available at specified timepoints were analyzed.","reportingStatus":"POSTED","timeFrame":"From Week 0 to Week 1, Week 0 to Week 5, and Week 0 to Week 10","title":"B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab","type":"SECONDARY","unitOfMeasure":"mg*hour (h)/Liter (L)"}